ACM
CYTK icon

ACT Capital Management’s Cytokinetics CYTK Stock Holding History

ACT Capital Management’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.05M Sell
47,500
-17,000
-26% -$1.22M 2.64% 11
2026
Q1 		$4.25M Hold
64,500
– – 3.34% 11
2025
Q4 		$4.1M Buy
+64,500
New +$4.01M 3.31% 11

Other funds holding CYTK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

ACT Capital Management's CYTK Position: Q2 2026 in Review

ACT Capital Management reduced its Cytokinetics (CYTK) stake by 26% in Q2 2026, selling an estimated $1.22M and leaving 47,500 shares worth $4.05M. The position accounts for 2.64% of the portfolio, ranked #11.

ACT Capital Management first reported a position in CYTK in Q4 2025 and has held it in 3 quarters since. The position peaked at $4.25M in Q1 2026. 482 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

  • ACT Capital Management held 47,500 shares of Cytokinetics worth $4.05M as of Q2 2026.
  • ACT Capital Management sold 17,000 Cytokinetics shares in Q2 2026, an estimated $1.22M.
  • Cytokinetics made up 2.64% of ACT Capital Management's portfolio in Q2 2026, its #11 holding.
  • ACT Capital Management first reported a position in Cytokinetics in Q4 2025 and has held it in 3 quarters since.
  • ACT Capital Management's Cytokinetics position peaked at $4.25M in Q1 2026.
  • 482 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on ACT Capital Management's 13F filing for Q2 2026, filed 29 Jul 2026.